The Recent Pullback Must Have Dismayed Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) Insiders Who Own 49% of the Company

Simply Wall StDec 18 17:13 ET

Chengdu Easton Biopharmaceuticals (688513.SH): Participating in the national pharmaceutical centralized procurement and expected to be selected.

On December 13, Glorious Exchange reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced its participation in the bidding work organized by the National Joint Procurement Office for the tenth batch of national centralized pharmaceutical procurement. According to the announcement published on December 12, 2024, on the Shanghai Sunlight Medical Procurement Network, the company’s Sodium Gluconate Injection and Nicorandil Injection are proposed to be awarded in this centralized procurement.

Gelonghui FinanceDec 13 05:44 ET

Chengdu Easton Biopharmaceuticals (688513.SH): The company did not implement share repurchases in November.

Gelonghui reported on December 2 that chengdu easton biopharmaceuticals (688513.SH) announced that in November 2024, the company did not implement share repurchases. As of the end of November 2024, the company has cumulatively repurchased 3,316,769 shares through centralized bidding, accounting for 1.8788% of the company’s current total share capital, with a highest purchase price of 56.05 yuan/share, a lowest price of 28.12 yuan/share, and a total transaction amount of 123,694,177.73 yuan (excluding stamp duty, transaction commissions, and other transaction costs).

Gelonghui FinanceDec 2 04:59 ET

Chengdu Easton Biopharmaceuticals Obtain Drug Registration for Ruxolitinib Phosphate Tablets

MT NewswiresNov 22 02:14 ET

Chengdu Easton Biopharmaceuticals (688513.SH): The phosphate lebrutinib tablets have obtained a pharmaceutical registration certificate.

Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company recently received approval from the National Medical Products Administration for the issuance of...

Zhitong FinanceNov 21 03:51 ET

Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Simply Wall StOct 31 23:13 ET